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Limited proteolysis of the surface of type 1 Streptococcus pyogenes by pepsin gives rise to fragment Pep 
Ml of Mr 20270 as the main product which covers the N-terminal part of the M protein. The amino acid 
sequence was determined of the N-terminal region of the M protein representing the most exposed part 
of the molecule on the surface fibrils of streptococcal cells, which seems to be very important for the differen- 
tiation of the individual serological types. The sequence differs from the homologous N-terminal sequences 
of types 5, 6 and 24, and shows a homology with sequences repeating in the chain of type 24. Fragment 
Pep Ml binds to fibrinogen; the absence of its 30 N-terminal amino acid residues, however, abolishes this 
interaction which is believed to play a role in the virulence of S. pyogenes. 
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1. INTRODUCTION 
The M protein which is present in fibrils on the 
surface of streptococcal cells is the only known 
factor of the virulence of Streptococcus pyogenes 
[I]. This property of the M protein is neutralized 
by the production of protective opsonic antibodies 
against he about 80 known serological types of the 
M protein of S. pyogenes. The single chain 
molecule is present in the fibrils as a dimer in the 
form of an a-helical coiled-coil structure [2]. The 
antiopsonic mechanism of the M proteins has not 
yet been elucidated; some authors [3] believe that 
the binding of fibrinogen, a non-type-specific 
ability of the M protein, plays a role in this 
mechanism. The isolated M protein was found to 
be an unsuitable antigen for vaccination against 
streptococcal infections since the immune cross 
reactions of some of its types with heart tissues 
may cause acute rheumatic fever [4]. A solution 
seems to be offered by the preparation of a syn- 
thetic peptide vaccine containing the antigenic 
determinants of the M protein which would bring 
about the production of protective antibodies and 
yet be free of the segments responsible for the for- 
mation of cross reacting antibodies and toxic ef- 
fects [5]. 
The determination of the general regularities of 
the molecular architecture of various M protein 
types, the investigation of the fibrinogen binding 
region obviously existing in all types and especially 
the practical aspect of the problem, i.e. the 
preparation of synthetic vaccines, require informa- 
tion on amino acid sequences of the individual M 
protein types. At present, sequence data are 
available for the N-terminal regions of types 5, 6 
[6] and 24 [7]; the nucleotide sequence for type 6, 
permitting the primary structure of its whole 
polypeptide chain to be derived, was reported 
recently [8]. We decided to start our comparative 
studies with type 1. 
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2. MATERIALS AND METHODS 
The cultivation of type 1 S. pyogenes strain 
CNCTC 40/58 and its extraction with limited pro- 
teolysis by pepsin as well as the fractionation of the 
crude extract by affinity chromatography on im- 
mobilized fibrinogen, completed by gel chroma- 
tography and the identification of the M protein in 
the fractionated material, are described elsewhere 
(Kiihnemund, 0. et al., in preparation). The 
amino acid analyses were effected by conventional 
procedures in a Durrum model D-500 amino acid 
analyzer. The sequence studies were performed by 
automatic degradation of approx. 5 nmol of sam- 
Fig. 1. SDS-polyacrylamide g l electrophoresis of the 
pepsin extract. Lanes: A, M, standards (Mr x 10-3), 
band 1 (69), band 2 (4% band 3 (28), band 4 (23); B, 
crude extract; C, ~brinogen-binding materiaf after 
affinity chromatography. I-III, bands of peptic 
fragments. 
ple in an Applied Biosystems (Foster City, CA, 
USA) model 470 A protein sequencer following a 
standard program (03RPTH) supplied, as well as 
the reagents, by the instrument’s manufacturer. 
The average repetitive yield of the degradation was 
94.5%. The amino acid phenylthiohydantoins 
were identified by HPLC on an Ultrasphere ODS 
column eluted by an acetonitrile gradient in acetate 
buffer (0.03 M, pH 4.2) using a Beckman liquid 
chromatography system and a Shimadzu in- 
tegrator. 
3. RESULTS AND DISCUSSION 
3.1. Characterization of peptic fragments of 
M protein 
The result of the basic fractionation of the crude 
pepsin extract is shown in fig. 1. Three large peptic 
fragments were found in bands I-III, of which 
component II does not bind to fibrinogen whereas 
components I and III (the last one, barely visible in 
the crude extract) are retarded during affinity 
chromatography. 
component I is the main product of limited pep- 
tic hydrolysis and will be referred to as fragment 
Pep Ml. It contains a total of 177 amino acid 
residues (table 1); its Mr calculated from the amino 
acid composition is 20270. The N-terminal se- 
quence of Pep Ml is 
10 
Val-Ala-Gly-Arg-Asp-Phe-Lys-Arg-Ala-Glu-Glu- 
20 
Leu-Glu-Lys-Ala-Lys-Gln-Ala-Leu-Glu-Asp- 
30 
Lys-Glu-Leu-Gln-Gln-Asp-Tyr-X-Leu; 
the residues in positions 23 and 38 have not been 
identified unambiguously. 
The N-terminal sequence of component II is 
Lys-Glu-Leu-Gln-Gln-Asp-Tyr-Asp-Leu-Ala-Lys- 
Glu-Ser-Thr-Ser-(Arg)-Lys-(Pro)-Gln-(Gly)- 
Ser-Glu-Lys-Lys-Leu; 
the residues in brackets have not been identified 
unambiguously. The sequence of the first 9 
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Table 1 
Amino acid composition of fragments 
Amino 
acid 
moi/mol 
I Found in I--@. II 
sequence I-30) 
of res. 
l-30 
Asp 
Thr 
Ser 
GIU 
Pro 
Gly 
Ala 
CYs 
Val 
Met 
Ile 
Leu 
Tyr 
Phe 
His 
Lys 
Arg 
Trp 
19.0(19) 
8.1(8) 
13.0(13) 
40.8(41) 
0.7(l) 
4.W) 
17.9(18) 
3.1(3) 
0.9(l) 
6.3(6) 
24.4(24) 
4.1(4) 
1.7(2) 
1.9(2) 
19.0(19) 
ll.O(ll) 
3 16 
1 7 
13 
7 34 
1 
1 4 
4 14 
1 2 
1 
6 
4 20 
4 
1 1 
2 
5 14 
3 8 
Total 177 30 147 
15.9 
6.7 
10.5 
35.1 
0.7 
3.7 
13.7 
- 
2.0 
0.8 
6.3 
20.0 
3.3 
0.6 
1.7 
14.5 
8.1 
- 
residues can be aligned with positions 31-39 of 
fragment Pep Ml, the region which follows ex- 
tending the partial sequence of the type 1 M pro- 
tein up to residue 55, The formation of component 
II by cleavage of the bond Leu(SO)-Lys(31) of the 
M protein chain is in agreement with the known 
specificity of pepsin. The sequence provides 
evidence that component II, even though it does 
not bind to ~brinogen, is a part of the M protein 
corresponding to Pep Ml minus 30 residues at its 
N-terminus (cf. table l).~ 
Component III is a minor product of extraction; 
the possibility cannot be excluded that it arises 
from secondary cleavage of Pep Ml and hence no 
conclusions on its interaction with fibrinogen can 
be made from the course of the affinity 
chromatography. The mixture of component III 
with Pep Ml yields a homogeneous sequence, 
therefore it probably covers the same region of the 
M protein but is shorter at the C-terminus. The C- 
$44 
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I res.l-177 Fib.t 
41 w 
II rer.31-177 Fib.- 
+-----& III res.l*? . 
Fig.2. Peptic fragments and their binding to fibrinogen. 
The number of arrows indicates the preference of peptic 
cleavage. The binding of fragment III has not been 
determined beyond doubt (cf. text). 
terminal parts of the M protein chain are not 
released into the peptic extract. 
The mutual arrangement of the fragments is 
shown in fig.2. Fibrinogen interacts with fragment 
Pep Ml representing on the fibrils the most ex- 
posed N-terminal part of the M protein; fragment 
II, which is shorter by 30 residues at its N- 
terminus, lacks this binding ability. 
M protein types 
A comparison of the N-terminal sequences [6] of 
types 5,6 and 24 so far determined reveals a mark- 
ed homology; an alignment of the sequence of type 
1 with these data is shown in fig.3. As is obvious 
from the top four lines, the homology of type 1 
(supporting the assignment of fragment Pep Ml to 
the N-terminus of the M protein) is restricted to the 
first four positions only; the arginine residue is 
conserved in all cases. In contrast, a comparison 
with the closely related sequences of the internal 
part of the chain of type 24 [9] indicates a marked 
relationship with the N-terminus of type 1. A 
similar relationship with the internal region of type 
24 is suggested by our preliminary data (unpub- 
Iished) on the N-terminus of type 12 M protein. 
The binding of the fibrinogen molecule to the 
extended N-terminal region of the M protein 
represents a certain restriction to the accessibility 
of the internal part of its chain. This fact increases 
the importance of the short exposed N-terminal 
region of the M protein as a binding site for op- 
sonic antibodies. 
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TYP@ 5 TVTRGTISDPQ~KEAL~~~L~NHDLKTK~EGLKT~~GLKTE~EGLKT~~GL 
Type 6 R~PRGTVEMPDW1RELL‘r\TKYD~NS~Q~~DKLTTE~TDQTJ~LTTE~~L 
Type 24 VATRSQTDTSEKVQE~DS~E~E~TT~KL 
TYPO 1 VAGRaFKRAEELEKAK&ALEDQ~KDLETEIlKELQQDYDLAKESTSrKpQgSElUil 
CB3 N-FSTADSAKIKTLEAEKAAlEAEKADlEKAlEGAM 
CB4 N'!?STADSAKIKTLEAEKAAlEARQADlEKAlEGAM 
CB5 ~FSTADSAK~KTlEA~~AlEAR~4Dl~DAl~L~GA~ 
CB6 ~FSTADSAKI~TlEAE~A~EARQAE ~E~lEG~~ 
CB7 ~FSTA~AKIKTlEAEKAAl~R~DlE~lEGAM 
Fig.3. Alignment of N-terminal sequences of types 5, 6 161, 24 171 and 1. The positions identical with type 1 are given 
in bold-face letters; CB3-CB7 are sequences of cyanogen bromide fragments from the internai part of the chain of type 
24 [9]. Lower-case l tters indicate positions not identified unambiguously. 
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